Literature DB >> 23339300

Protein misfolding in disease and small molecule therapies.

Cláudio M Gomes1.   

Abstract

A large number of human disorders are caused by defects in protein folding resulting from genetic mutations or adverse physiological conditions, and these are collectively referred to protein misfolding diseases. Such disorders imply dysfunction of a cellular process either as a result of a toxic gain of function due to protein aggregation, or loss of function due to protein instability, inefficient folding or defective trafficking. For a number of cases, drugs acting directly on the affected protein have been found to prevent misfolding and rescue function. This brief review will illustrate molecular mechanisms through which small molecules acting as folding correctors can prevent excessive protein buildup or recover faulty protein conformers, thus acting as effective therapeutic pharmacological chaperones. As background, the principles underlying the thermodynamics and kinetics of the protein folding reaction will be overviewed, as well as pathways leading to the formation of misfolding. The mechanism of action of small molecule correctors will then be discussed in light of these basic principles using illustrative examples referring to drugs that are effective over proteins involved in trafficking and folding diseases, amyloid aggregation disorders and metabolic deficiencies. An outlook on synergistic effects between different folding correctors and their combination with proteostasis regulators will also be addressed, as a relevant strategy towards the design of more effective therapies against protein folding diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23339300     DOI: 10.2174/1568026611212220002

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  17 in total

1.  Rescue of protein expression defects may not be enough to abolish the pro-arrhythmic phenotype of long QT type 2 mutations.

Authors:  Matthew D Perry; Chai Ann Ng; Kevin Phan; Erikka David; Kieran Steer; Mark J Hunter; Stefan A Mann; Mohammad Imtiaz; Adam P Hill; Ying Ke; Jamie I Vandenberg
Journal:  J Physiol       Date:  2016-05-27       Impact factor: 5.182

2.  Novel small molecule binders of human N-glycanase 1, a key player in the endoplasmic reticulum associated degradation pathway.

Authors:  Bharath Srinivasan; Hongyi Zhou; Sreyoshi Mitra; Jeffrey Skolnick
Journal:  Bioorg Med Chem       Date:  2016-08-13       Impact factor: 3.641

3.  Insights into human phosphoglycerate kinase 1 deficiency as a conformational disease from biochemical, biophysical, and in vitro expression analyses.

Authors:  Angel L Pey; Maristella Maggi; Giovanna Valentini
Journal:  J Inherit Metab Dis       Date:  2014-05-17       Impact factor: 4.982

4.  Design, synthesis and photochemical properties of the first examples of iminosugar clusters based on fluorescent cores.

Authors:  Mathieu L Lepage; Antoine Mirloup; Manon Ripoll; Fabien Stauffert; Anne Bodlenner; Raymond Ziessel; Philippe Compain
Journal:  Beilstein J Org Chem       Date:  2015-05-06       Impact factor: 2.883

5.  Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design.

Authors:  D Sean Froese; Amit Michaeli; Thomas J McCorvie; Tobias Krojer; Meitav Sasi; Esther Melaev; Amiram Goldblum; Maria Zatsepin; Alexander Lossos; Rafael Álvarez; Pablo V Escribá; Berge A Minassian; Frank von Delft; Or Kakhlon; Wyatt W Yue
Journal:  Hum Mol Genet       Date:  2015-07-21       Impact factor: 6.150

6.  Functional characterization and categorization of missense mutations that cause methylmalonyl-CoA mutase (MUT) deficiency.

Authors:  Patrick Forny; D Sean Froese; Terttu Suormala; Wyatt W Yue; Matthias R Baumgartner
Journal:  Hum Mutat       Date:  2014-12       Impact factor: 4.878

7.  The role of protein denaturation energetics and molecular chaperones in the aggregation and mistargeting of mutants causing primary hyperoxaluria type I.

Authors:  Noel Mesa-Torres; Israel Fabelo-Rosa; Debora Riverol; Cristina Yunta; Armando Albert; Eduardo Salido; Angel L Pey
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

Review 8.  Functional Amyloid Signaling via the Inflammasome, Necrosome, and Signalosome: New Therapeutic Targets in Heart Failure.

Authors:  Traci L Parry; Jason H Melehani; Mark J Ranek; Monte S Willis
Journal:  Front Cardiovasc Med       Date:  2015-05-19

Review 9.  Neurodegeneration in Friedreich's ataxia: from defective frataxin to oxidative stress.

Authors:  Cláudio M Gomes; Renata Santos
Journal:  Oxid Med Cell Longev       Date:  2013-07-09       Impact factor: 6.543

10.  Small molecules present in the cerebrospinal fluid metabolome influence superoxide dismutase 1 aggregation.

Authors:  Joana S Cristóvão; Sónia S Leal; Isabel Cardoso; Cláudio M Gomes
Journal:  Int J Mol Sci       Date:  2013-09-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.